Roche is testing a new multiple sclerosis drug that looks very promising.
Roche’s new drug for treating multiple sclerosis is called Ocrelizumab. The drug has performed well in three late-stage studies and is effective at treating and slowing the disease. A study of 732 patients with primary progressive multiple sclerosis saw positive results. There currently isn’t a treatment for primary progressive multiple sclerosis, reports Nature World Report.
The new drug being worked on by Roche to treat multiple sclerosis has been found 46% to 47% successful at stopping relapses. Roughly 10% of patients see side effects from the drug and 24% of patients saw a slowing in the disease’s progression after 12 weeks, Nature World Report notes.
“The results of these three pivotal trials have the potential to transform the treatment of MS,” Sandra Horning, chief medical officer at Genentech, told Tech Times. “Ocrelizumab is the first investigational medicine to significantly reduce disability progression in people with relapsing MS and people with primary progressive MS – a form of MS with no approved treatments.”
More From InvestorPlace:
